NO146058B - ANALOGUE PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BENZAMIDES. - Google Patents
ANALOGUE PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BENZAMIDES. Download PDFInfo
- Publication number
- NO146058B NO146058B NO761977A NO761977A NO146058B NO 146058 B NO146058 B NO 146058B NO 761977 A NO761977 A NO 761977A NO 761977 A NO761977 A NO 761977A NO 146058 B NO146058 B NO 146058B
- Authority
- NO
- Norway
- Prior art keywords
- methoxy
- group
- reacted
- hydroxyethyl
- ethyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- 229940054066 benzamide antipsychotics Drugs 0.000 title claims description 7
- 150000003936 benzamides Chemical class 0.000 title claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- ZQSFLXDMGBSJKV-UHFFFAOYSA-N ethyl 2-methoxy-5-sulfamoylbenzoate Chemical compound CCOC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC ZQSFLXDMGBSJKV-UHFFFAOYSA-N 0.000 claims description 7
- JQXLWCCKZDDEMZ-UHFFFAOYSA-N 2-[2-(aminomethyl)pyrrolidin-1-yl]ethanol Chemical compound NCC1CCCN1CCO JQXLWCCKZDDEMZ-UHFFFAOYSA-N 0.000 claims description 4
- BQQVEASFNMRTBA-UHFFFAOYSA-N 2-[4-(3-aminopropyl)piperazin-1-yl]ethanol Chemical compound NCCCN1CCN(CCO)CC1 BQQVEASFNMRTBA-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- NPWLBAJVJBYMTI-UHFFFAOYSA-N N-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]-2-methoxy-4-nitrobenzamide Chemical compound COC1=C(C(=O)NCCCN2CCN(CC2)CCO)C=CC(=C1)[N+](=O)[O-] NPWLBAJVJBYMTI-UHFFFAOYSA-N 0.000 claims description 3
- XGADZAZNQPXBES-UHFFFAOYSA-N OP(O)(=O)OP(=O)(O)O.COC1=C(C(=O)NCCCN2CCN(CC2)CCO)C=CC(=C1)N Chemical compound OP(O)(=O)OP(=O)(O)O.COC1=C(C(=O)NCCCN2CCN(CC2)CCO)C=CC(=C1)N XGADZAZNQPXBES-UHFFFAOYSA-N 0.000 claims description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- PUIXOJJCTJVSBX-UHFFFAOYSA-N 2-[2-aminoethyl(ethyl)amino]ethanol Chemical compound NCCN(CC)CCO PUIXOJJCTJVSBX-UHFFFAOYSA-N 0.000 claims description 2
- DJDAPLBWGIXUAG-UHFFFAOYSA-N 2-methoxy-4-nitrobenzoyl chloride Chemical compound COC1=CC([N+]([O-])=O)=CC=C1C(Cl)=O DJDAPLBWGIXUAG-UHFFFAOYSA-N 0.000 claims description 2
- XFZMCFJADJFEBB-UHFFFAOYSA-N 2-methoxy-5-sulfamoylbenzoyl chloride Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1C(Cl)=O XFZMCFJADJFEBB-UHFFFAOYSA-N 0.000 claims description 2
- RAYGQIXIIBTRCF-UHFFFAOYSA-N 3-[2-(aminomethyl)pyrrolidin-1-yl]propan-1-ol Chemical compound NCC1CCCN1CCCO RAYGQIXIIBTRCF-UHFFFAOYSA-N 0.000 claims description 2
- OLJXRTRRJSMURJ-UHFFFAOYSA-N 4-amino-2-methoxybenzoic acid Chemical compound COC1=CC(N)=CC=C1C(O)=O OLJXRTRRJSMURJ-UHFFFAOYSA-N 0.000 claims description 2
- RVEATKYEARPWRE-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxybenzoic acid Chemical compound COC1=CC(N)=C(Cl)C=C1C(O)=O RVEATKYEARPWRE-UHFFFAOYSA-N 0.000 claims description 2
- GSFGGUVBFJQNQQ-UHFFFAOYSA-N 5-ethylsulfonyl-2-methoxybenzoyl chloride Chemical compound CCS(=O)(=O)C1=CC=C(OC)C(C(Cl)=O)=C1 GSFGGUVBFJQNQQ-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- NYBODIXASROHMM-UHFFFAOYSA-N [1-(2-benzhydryloxyethyl)pyrrolidin-2-yl]methanamine Chemical compound NCC1CCCN1CCOC(C=1C=CC=CC=1)C1=CC=CC=C1 NYBODIXASROHMM-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- UUARTHQJSZTOEM-UHFFFAOYSA-N methyl 5-ethylsulfonyl-2-methoxybenzoate Chemical compound CCS(=O)(=O)C1=CC=C(OC)C(C(=O)OC)=C1 UUARTHQJSZTOEM-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 10
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- -1 cyanomethyl Chemical group 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 230000003474 anti-emetic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- VXEGSRKPIUDPQT-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)piperazin-1-yl]aniline Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(N)=CC=2)CC1 VXEGSRKPIUDPQT-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000006229 carbon black Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000005049 silicon tetrachloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 2
- 229960004161 trimethobenzamide Drugs 0.000 description 2
- CFGDUGSIBUXRMR-UHFFFAOYSA-N 1,2-dihydropyrrol-2-ide Chemical class C=1C=[C-]NC=1 CFGDUGSIBUXRMR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OZAWFSRMXIZJTF-UHFFFAOYSA-N 1-(2-amino-2-methylpyrrolidin-1-yl)ethanone Chemical compound C(C)(=O)N1C(CCC1)(N)C OZAWFSRMXIZJTF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BVWGPIUZEMCWHS-UHFFFAOYSA-N 4-amino-N-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]-2-methoxybenzamide Chemical compound COC1=C(C(=O)NCCCN2CCN(CC2)CCO)C=CC(=C1)N BVWGPIUZEMCWHS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DQTRYXANLKJLPK-UHFFFAOYSA-N chlorophosphonous acid Chemical class OP(O)Cl DQTRYXANLKJLPK-UHFFFAOYSA-N 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000007928 imidazolide derivatives Chemical class 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Otolaryngology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
Foreliggende oppfinnelse angår en analogifremgangsmåte for fremstilling av nye substituerte benzamider med den generelle formel (I)3 deres kvaternære ammoniumsalter, oksyder, farmaseutisk akseptable syreaddisjonssalter, høyre-og venstredreiende isomerer derav. The present invention relates to an analogous process for the production of new substituted benzamides with the general formula (I)3, their quaternary ammonium salts, oxides, pharmaceutically acceptable acid addition salts, dextrorotatory and levorotatory isomers thereof.
Benzamidene som fremstilles ifølge oppfinnelsen The benzamides produced according to the invention
har formelen: has the formula:
der: there:
A angir en alkylgruppe med 1-4 karbonatomer ; W angir en alkylengruppe med 1-4 karbonatomer; B angir en gruppe med formelen A denotes an alkyl group with 1-4 carbon atoms; W denotes an alkylene group of 1-4 carbon atoms; B denotes a group with the formula
der FL angir en alkylgruppe med 1-5 karbonatomer og R ? en hydroksyalkylgruppe med 1-5 karbonatomer where FL denotes an alkyl group with 1-5 carbon atoms and R ? a hydroxyalkyl group with 1-5 carbon atoms
I IN
eller en 4-hydroksyalkyl-l-piperazinylgruppe, or a 4-hydroxyalkyl-1-piperazinyl group,
eller en gruppe med formelen or a group with the formula
i in
der R er en hydroksyalkylgruppe med 1-5 karbonatomer, en acetyl-gruppe eller en benzhydryloksyalkylgruppe; where R is a hydroxyalkyl group with 1-5 carbon atoms, an acetyl group or a benzhydryloxyalkyl group;
Y angir et hydrogenatom, en nitrogruppe eller aminogruppe; og Y represents a hydrogen atom, a nitro group or an amino group; and
Z angir et hydrogenatom, et halogenatom, en alkylsulfonylgruppe med 1-5 karbonatomer eller en gruppe SC^NR^R^ der R3 og R^ som kan være like "eller forskjellige angir hydrogen eller en lavere alkylgruppe med 1-5 karbonatomer. Z denotes a hydrogen atom, a halogen atom, an alkylsulfonyl group with 1-5 carbon atoms or a group SC^NR^R^ where R 3 and R^ which may be the same or different denote hydrogen or a lower alkyl group with 1-5 carbon atoms.
Benzamidene som fremstilles ifølge oppfinnelsen kan fremstilles ved å omsette en forbindelse med formelen: The benzamides produced according to the invention can be produced by reacting a compound with the formula:
-der D angir en hydroksygruppe eller en organisk rest og A og Y samt Z har den ovenfor angitte betydning, med et amin med den generelle formel (III): -where D denotes a hydroxy group or an organic residue and A and Y as well as Z have the above meaning, with an amine of the general formula (III):
der W og B har den ovenfor angitte betydning, eller ved å omsette deres reaktive derivater. where W and B have the above meaning, or by reacting their reactive derivatives.
I utgangsforbindelsen (II) inkluderer den organiske rest grupper som er i stand til å danne reaktive syrederivater. Disse kan være lavere alkylestere slik som metyl-, etyl-, propyl-, butyl-, isobutyl-, pentyl-, isopentylestere osv., reaktive sure estere slik som cyanometyl- eller metoksymetylestere eller N-hydroksyimidestere, eller eventuelt substituerte aromatiske esterej syrehalogenider; syrehydrazider ; syreazider; symmetriske anhydrider; blandede anhydrider, f.eks. dannet med karbonsyreestere eller halogenmaursyreestere ; azolider slik som triazolider, tetrazolider eller imidazolider; sure isotiocyanater; substitu- In the starting compound (II), the organic residue includes groups capable of forming reactive acid derivatives. These can be lower alkyl esters such as methyl, ethyl, propyl, butyl, isobutyl, pentyl, isopentyl esters, etc., reactive acid esters such as cyanomethyl or methoxymethyl esters or N-hydroxyimide esters, or optionally substituted aromatic esters and acid halides; acid hydrazides; acid azides; symmetrical anhydrides; mixed anhydrides, e.g. formed with carboxylic acid esters or haloformic acid esters; azolides such as triazolides, tetrazolides or imidazolides; acid isothiocyanates; substitute
erte w-trihalogenacetofenoner; substituerte a-oksobenzenaceto-nitriler; benzamider substituert i kjernen. pea w-trihaloacetophenones; substituted α-oxobenzeneacetonitriles; benzamides substituted in the core.
Aminet kan delta i reaksjonen i form av et av sine reaktive derivater som eventuelt kan isoleres. Som eksem- The amine can participate in the reaction in the form of one of its reactive derivatives which can possibly be isolated. As exem-
pel skal nevnes reaksjonsproduktene av aminet med fosforklori- should be mentioned the reaction products of the amine with phosphorus chloride
der, fosforoksyklorid, dialkyl-, diaryl- eller ortofenylenklor-fosfitter, alkyl- eller aryldiklorfosfitter, aminisotiocyanat, der, phosphorus oxychloride, dialkyl, diaryl or orthophenylene chlorophosphites, alkyl or aryl dichlorophosphites, amine isothiocyanate,
det symmetriske eller ikke-symmetriske sulfamid av aminet, the symmetric or unsymmetrical sulfamide of the amine,
det tilsvarende symmetriske urinstoff, og de tilsvarende enami- the corresponding symmetrical urea, and the corresponding enami-
ner. De ovenfor angitte reaktive derivater kan omsettes med syren in situ eller etter foregående isolasjon. down. The above-mentioned reactive derivatives can be reacted with the acid in situ or after previous isolation.
Et er også mulig å gjennomføre reaksjonen mellom It is also possible to carry out the reaction between
den frie syre og fritt amin i nærvær av et kondensasjonsmiddel the free acid and free amine in the presence of a condensing agent
slik som f.eks. silisiumtetraklorid, fosforsyreanhydrid, et karbo-diimid slik som dicykloheksylkarbodiimid, eller alkoksyacetylener slik som metoksy- eller etoksyacetylen. such as e.g. silicon tetrachloride, phosphoric anhydride, a carbodiimide such as dicyclohexylcarbodiimide, or alkoxyacetylenes such as methoxy or ethoxyacetylene.
Amideringsreaksjonen ifølge oppfinnelsen kan gjen-nomføres i nærvær eller i fravær av et oppløsningsmiddel. Sys-temene som benyttes som oppløsningsmiddel er inerte med henblikk The amidation reaction according to the invention can be carried out in the presence or in the absence of a solvent. The systems used as solvents are purposefully inert
på amideringsreaksjonen og er f.eks. alkoholer, polyoler, benzen, toluen, dioksan, kloroform eller dietylenglykoldimetyleter. Det er også mulig å bruke et overskudd av aminet som brukes som ut-gangsstoff som oppløsningsmiddel. Det kan være foretrukket å oppvarme reaksjonsblandingen under amideringen, f.eks. til kokepunktet for det ovenfor angitte oppløsningsmiddel. on the amidation reaction and is e.g. alcohols, polyols, benzene, toluene, dioxane, chloroform or diethylene glycol dimethyl ether. It is also possible to use an excess of the amine used as starting material as a solvent. It may be preferred to heat the reaction mixture during the amidation, e.g. to the boiling point of the above solvent.
Forbindelsene som oppnås ifølge oppfinnelsen, kan The compounds obtained according to the invention can
hvis nødvendig, omsettes med en farmasøytisk akseptabel mineral-syre eller en organisk syre slik saltsyre, bromhydrogensyre, svovelsyre, fosforsyre, oksalsyre, eddiksyre, vinsyre, sitronsyre eller metansulfonsyre for å oppnå syreaddisjonssalter. if necessary, react with a pharmaceutically acceptable mineral acid or an organic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, oxalic acid, acetic acid, tartaric acid, citric acid or methanesulfonic acid to obtain acid addition salts.
De kan også, hvis nødvendig, omsettes med et alkylhalogenid eller et sulfat for å oppnå det tilsvarende kvaternære ammoniumsalt. They can also, if necessary, be reacted with an alkyl halide or a sulfate to obtain the corresponding quaternary ammonium salt.
For å illustrere oppfinnelsen gis det nedenfor en To illustrate the invention, a is given below
del utførelseseksempler. share execution examples.
Eksempel 1: N-(l-(2'-hydroksyetyl)-2-pyrrolidinylmetyl)-2-metoksy-5-sulfamoylbenzamid. 48 g etyl-2-metoksy-5-sulfamoylbenzoat, 17 g vann og 32 g 1-(2-hydroksyetyl)-2-aminometylpyrrolidin ble tilsatt til en 250 ml kolbe. Blandingen ble oppvarmet på et vannbad inntil en prøve ble funnet å være totalt oppløselig i fortynnet eddiksyre. Oppløsningen ble avkjølt og deretter fortynnet med 300 ml vann. De dannede krystaller ble filtrert ved avsugning, vasket med vann og tørket ved 40°C. Det oppnådde benzamid ble renset ved omdanning til acetat fulgt av frigjøring av basen. Example 1: N-(1-(2'-hydroxyethyl)-2-pyrrolidinylmethyl)-2-methoxy-5-sulfamoylbenzamide. 48 g of ethyl 2-methoxy-5-sulfamoylbenzoate, 17 g of water and 32 g of 1-(2-hydroxyethyl)-2-aminomethylpyrrolidine were added to a 250 ml flask. The mixture was heated on a water bath until a sample was found to be completely soluble in dilute acetic acid. The solution was cooled and then diluted with 300 ml of water. The formed crystals were filtered by suction, washed with water and dried at 40°C. The benzamide obtained was purified by conversion to acetate followed by liberation of the base.
Det ble oppnådd 39 g N-(1-(2'-hydroksyetyl)-2-pyrro-lidnylmetyl)-2-metoksy-5-sulfamoylbenzamid i et utbytte på 59% og med et smeltepunkt på 135-136°C. Eksempel 2: N-(1-(3'-hydroksypropyl)-2-pyrrolidinylmetyl)-2-■ 39 g of N-(1-(2'-hydroxyethyl)-2-pyrrolidnylmethyl)-2-methoxy-5-sulfamoylbenzamide were obtained in a yield of 59% and with a melting point of 135-136°C. Example 2: N-(1-(3'-hydroxypropyl)-2-pyrrolidinylmethyl)-2-■
metoksy-5-etylsulfonylbenzamidhydroklorid. methoxy-5-ethylsulfonylbenzamide hydrochloride.
38,8 g 2-metoksy-5-etylsulfonylbenzosyremetylester, 13j5 ml vann og 28,4 g l-(3-hydroksypropyl)-2-aminometyl-pyrroli-din ble tilsatt til en 250 ml kolbe. Blandingen ble oppvarmet i 38.8 g of 2-methoxy-5-ethylsulfonylbenzoic acid methyl ester, 13.5 ml of water and 28.4 g of 1-(3-hydroxypropyl)-2-aminomethyl-pyrrolidine were added to a 250 ml flask. The mixture was heated in
.10 timer til 85-90°C. Etteri fordamping ble resten oppløst i 200 ml etanol og oppløsningen ble surgjort til en pH-verdi på 1 med alkoholisk saltsyre. Tetrahydrofuran ble tilsatt og de dannede krystaller ble filtrert, vasket og tørket' i en ovn ved 50°C. Det ble oppnådd 35 g N-(1-(3'-hydroksypropyl)-2-pyrrolidinylmetyl)-2-"-••''metoksy-5-etylsulfonylbenzamidhydrok'lorid 'etter omkrystallisering fra alkohol. Utbyttet var 55, 5% og smeltepunktet l84-l86°C). Eksempel 3'- N- (1' -acetyl-2 ' -pyrrolidinylmetyl)-2-metoksy-5-sul famoylbenzamid. 48 g etyl-2-metoksy-5-sulfamoylbenzoat ble omsatt med 31,5 g N-acetyl-2-amino-metylpyrrolidin på samme måte som angitt ovenfor og dette resulterte i 3^,5 g N-(1'-acetyl-2'-pyrro-lidinylmetyl )-2-metoksy-5-sulfamoylbenzamid i et utbytte på 52,5$ og med et smeltepunkt på 204°C. .10 hours at 85-90°C. After evaporation, the residue was dissolved in 200 ml of ethanol and the solution was acidified to a pH value of 1 with alcoholic hydrochloric acid. Tetrahydrofuran was added and the crystals formed were filtered, washed and dried in an oven at 50°C. 35 g of N-(1-(3'-hydroxypropyl)-2-pyrrolidinylmethyl)-2-"-••''methoxy-5-ethylsulfonylbenzamide hydrochloride were obtained after recrystallization from alcohol. The yield was 55.5% and melting point 184-186°C).Example 3'-N-(1'-acetyl-2'-pyrrolidinylmethyl)-2-methoxy-5-sul famoylbenzamide. 48 g of ethyl-2-methoxy-5-sulfamoylbenzoate was reacted with 31.5 g of N-acetyl-2-amino-methylpyrrolidine in the same manner as stated above and this resulted in 3^.5 g of N-(1'-acetyl- 2'-pyrrolidinylmethyl)-2-methoxy-5-sulfamoylbenzamide in a yield of 52.5$ and with a melting point of 204°C.
Eksempel 4: N,(N,-etyl-N'-(2'-hydroksyetyl)aminoetyl)-2-metoksy-4-amino-5-klorbenzamid. Example 4: N,(N,-ethyl-N'-(2'-hydroxyethyl)aminoethyl)-2-methoxy-4-amino-5-chlorobenzamide.
6,1 g 2-metoksy-4-amino-5-klorbenzosyre og 8 g N-etyl-N-2-hydroksyetyletylendiamin ble tilsatt til en 250 ml kolbe. Blandingen ble oppvarmet til 100°C og det ble tilsatt 6.1 g of 2-methoxy-4-amino-5-chlorobenzoic acid and 8 g of N-ethyl-N-2-hydroxyethylethylenediamine were added to a 250 ml flask. The mixture was heated to 100°C and it was added
6,5 g fosforsyreanhydrid. Blandingen ble forsiktig oppvarmet til 110°C og temperaturen ble deretter hurtig hevet til 150-l60°C. Denne temperatur ble opprettholdt i \ time og deretter, etter av-kjøling til 100°C, ble det tilsatt 100 ml vann. Soda ble tilsatt etter at komponentene totalt var oppløst. Blandingen ble avkjølt og utfellingen ble filtrert, vasket med vann og tørket. Det ble oppnådd 6,6 g N-(N'-etyl-N1 -(2'-hydroksyetyl)aminoetyl)-2-metoksy-4- amino-5-klorbenzamid i et utbytte på 69,8% og med et smeltepunkt på 111-112°C. 6.5 g phosphoric anhydride. The mixture was gently heated to 110°C and the temperature was then rapidly raised to 150-160°C. This temperature was maintained for 1 hour and then, after cooling to 100°C, 100 ml of water was added. Soda was added after the components had completely dissolved. The mixture was cooled and the precipitate was filtered, washed with water and dried. 6.6 g of N-(N'-ethyl-N1-(2'-hydroxyethyl)aminoethyl)-2-methoxy-4-amino-5-chlorobenzamide were obtained in a yield of 69.8% and with a melting point of 111-112°C.
Eksempel 5: N-(1-(2'-benzhydryloksyety1)-2-pyrrolidinylmetyl)-2-metoksy-5-sulfamoylbenzamid. 99 g 1-(2'-benzhydryloksyetyl)-2-aminometylpyrroli-din og 500 ml metyletylketon ble tilsatt en en 4 liters kolbe. Blandingen ble avkjølt til 15°C og en oppløsning av 80 g 2-metoksy-5- sulfamoylbenzoylklorid.i 1500 ml metyletylketon ble tilsatt. Blandingen ble omrørt i 2 timer ved omgivelsestemperatur. Utfellingen som ble dannet, ble filtrert, vasket med en liten mengde metyletylketon og tørket. Hydrokloridet som ble oppnådd ble gjort alkalisk mens det var varmt med ammoniakk, og produktet ble krystallisert ved avkjøling. Krystallene ble filtrert, vasket og tørket i en ovn ved 50°C. Det ble oppnådd 88 g N-(l-(2'-benzhydryloksyetyl)-2-pyrrolidinylmetyl)-2-metoksy-5~sulfamoylbenzamid etter omkrystallisering fra etanol, filtrering gjennom kjønrøk og tørking. Utbyttet var 52,6% og smeltepunktet 124°C. Eksempel 6: 1-(2'-metoksy-4'-nitrobenzamidopropyl)-4-hydroksy-etylpiperazin. 45 g 1-(2'-hydroksyetyl)-4-(3'-aminopropyl)pipera-zin og l80 ml kloroform ble tilsatt til en 1 liters kolbe. En oppløsning av 51 g 2-metoksy-4-nitrobenzoylklorid ble helt i blandingen ved en temperatur på 5-10°C. Ved slutten av tilset-ningen ble blandingen bragt til omgivelsestemperatur og deretter oppvarmet i 1 til 1 1/4 time til 40-45°C. Vann ble tilsatt og kloroformen ble dampet av. Den oppnådde oppløsning ble filtrert ved bruk av kjønrøk og benzamidbasen ble utfelt ved tilsetning av 50g kaliumkarbonat. Etter dekantering ble produktet oppløst i metylklorid og den vandige oppløsning ble ekstrahert med metylenklorid. Example 5: N-(1-(2'-benzhydryloxyethyl)-2-pyrrolidinylmethyl)-2-methoxy-5-sulfamoylbenzamide. 99 g of 1-(2'-benzhydryloxyethyl)-2-aminomethylpyrrolidine and 500 ml of methyl ethyl ketone were added to a 4 liter flask. The mixture was cooled to 15°C and a solution of 80 g of 2-methoxy-5-sulfamoylbenzoyl chloride in 1500 ml of methyl ethyl ketone was added. The mixture was stirred for 2 hours at ambient temperature. The precipitate that formed was filtered, washed with a small amount of methyl ethyl ketone and dried. The hydrochloride obtained was made alkaline while hot with ammonia, and the product crystallized on cooling. The crystals were filtered, washed and dried in an oven at 50°C. 88 g of N-(1-(2'-benzhydryloxyethyl)-2-pyrrolidinylmethyl)-2-methoxy-5-sulfamoylbenzamide were obtained after recrystallization from ethanol, filtration through carbon black and drying. The yield was 52.6% and the melting point 124°C. Example 6: 1-(2'-methoxy-4'-nitrobenzamidopropyl)-4-hydroxyethylpiperazine. 45 g of 1-(2'-hydroxyethyl)-4-(3'-aminopropyl)piperazine and 180 ml of chloroform were added to a 1 liter flask. A solution of 51 g of 2-methoxy-4-nitrobenzoyl chloride was poured into the mixture at a temperature of 5-10°C. At the end of the addition, the mixture was brought to ambient temperature and then heated for 1 to 1 1/4 hours to 40-45°C. Water was added and the chloroform was evaporated. The solution obtained was filtered using carbon black and the benzamide base was precipitated by adding 50g of potassium carbonate. After decantation, the product was dissolved in methyl chloride and the aqueous solution was extracted with methylene chloride.
Den organiske fase ble tørket med kaliumkarbonat og metylenkloridet ble deretter destillert av i vakuum. Det olje-lignende benzamid som ble oppnådd ble renset ved dannelse av hydrokloridet og behandling' med ammoniakk. The organic phase was dried with potassium carbonate and the methylene chloride was then distilled off in vacuo. The oil-like benzamide obtained was purified by formation of the hydrochloride and treatment with ammonia.
Det ble oppnådd 59 g 1-(2'-metoksy-4'-nitrobenza-midopropyl )-4-hydroksyetylpiperazin i form av en olje og i et utbytte på 67,2%. Renhetsanalyse ved kvantitativ -bestemmelse i et ikke-vandig medium med perklorsyre ga 97,8%. 59 g of 1-(2'-methoxy-4'-nitrobenzamidopropyl)-4-hydroxyethylpiperazine were obtained in the form of an oil and in a yield of 67.2%. Purity analysis by quantitative determination in a non-aqueous medium with perchloric acid gave 97.8%.
Eksempel 7: N-(1-(2'-hydroksyetyl)-2-pyrrolidinylmetyl)-2-metoksy-5-etylsulfonylbenzamidhydroklorid. Example 7: N-(1-(2'-hydroxyethyl)-2-pyrrolidinylmethyl)-2-methoxy-5-ethylsulfonylbenzamide hydrochloride.
39 g l-(2-hydroksyetyl)-2-aminometylpyrrolidin, 250 ml metyletylketon og under opprettholdelse av temperaturen, mellom 5 og 10°C, 70 g 2-metoksy-5-etylsulfonylbenzoylklorid ble tilsatt til en 500 ml kolbe. Etter i omrøring over natt ble det krystall-inske produkt filtrert ved undertrykk, vasket med metyletylketon og tørket ved 45°C. Råproduktet ble omkrystallisert i 200 ml alkohol ved 95°C. Det ble oppnådd 73 g N-(l-(-2 '-hydroksyetyl)-2- pyrrolidinylmetyl)-2-metoksy-5-etylsulfonylbenzamidhydroklorid i et utbytte på 66, 5% og med et smeltepunkt på 175-178°C. Eksempel 8: N-(N'-etyl-N'-(2'-hydroksyetyl)-aminoetyl)-2-metoksy- 5-sul-f amoylbenzamid. 78 g etyl-2-rne<t>oks<y>-5-sulf amoylbenzoat, 27 ml vann og en 51 g N-éty-l-N-hydroksyetyletylendiamin ble tilsatt til en 250 mi" kolbe. Blandingen ble oppvarmet i 10 timer på et vannbad. Oppløsningen ble fortynnet og benzamidbasen deretter krystallisert,. Denne ..ble renset ved dannelse av hydrokloridet og utfelling av basen med 'ammoniakk. De oppnådde krystaller ble filtrert ved sug , vasket med vann til kloridionene alle var fjernet, og tørket i en ovn ved 40°C. 39 g of 1-(2-hydroxyethyl)-2-aminomethylpyrrolidine, 250 ml of methyl ethyl ketone and, maintaining the temperature, between 5 and 10°C, 70 g of 2-methoxy-5-ethylsulfonylbenzoyl chloride were added to a 500 ml flask. After stirring overnight, the crystalline product was filtered under reduced pressure, washed with methyl ethyl ketone and dried at 45°C. The crude product was recrystallized in 200 ml of alcohol at 95°C. 73 g of N-(1-(-2'-hydroxyethyl)-2- pyrrolidinylmethyl)-2-methoxy-5-ethylsulfonylbenzamide hydrochloride in a yield of 66.5% and with a melting point of 175-178°C. Example 8: N-(N'-ethyl-N'-(2'-hydroxyethyl)-aminoethyl)-2-methoxy- 5-sul-f amoylbenzamide. 78 g of ethyl-2-rne<t>ox<y>-5-sulfamoylbenzoate, 27 ml of water and a 51 g of N-ethyl-1-N-hydroxyethylethylenediamine were added to a 250 ml" flask. The mixture was heated for 10 hours at a water bath. The solution was diluted and the benzamide base then crystallized. This ..was purified by formation of the hydrochloride and precipitation of the base with ammonia. The crystals obtained were filtered by suction, washed with water until the chloride ions were all removed, and dried in a oven at 40°C.
Det ble oppnådd 66 g N-(N'-etyl-N'-(2'-hydroksy-etyl )aminoetyl)-2-metoksy-5-sulfamoylbenzamid i et utbytte på' 64% og med et smeltepunkt på<:>149-150°C. 66 g of N-(N'-ethyl-N'-(2'-hydroxy-ethyl)aminoethyl)-2-methoxy-5-sulfamoylbenzamide were obtained in a yield of 64% and with a melting point of <:>149 -150°C.
Eksempel 9: N-(l-(3'-hydroksypropyl)-2-pyrrolidinylmetyl)-2-metoksy-5-sulfamoylbenzamidhydroklorid. Example 9: N-(1-(3'-hydroxypropyl)-2-pyrrolidinylmethyl)-2-methoxy-5-sulfamoylbenzamide hydrochloride.
38,9 g etyl-2-metoksy-5-sulfamoylbenzoat, 13,5 ml vann og 28,4 g N-l-(3'-hydroksypropyl)-2-aminometylpyrrolidin ble tilsatt til en 250 ml kolbe. Blandingen ble oppvarmet i 10 timer ved 80°C og etter avkjøling ble 100 ml benzen tilsatt og oppløsningsmidlene ble destillert av. Blandingen ble avkjølt og 500 ml vann ble deretter tilsatt. De dannede krystaller ble fil- 38.9 g of ethyl 2-methoxy-5-sulfamoylbenzoate, 13.5 ml of water and 28.4 g of N-1-(3'-hydroxypropyl)-2-aminomethylpyrrolidine were added to a 250 ml flask. The mixture was heated for 10 hours at 80°C and after cooling, 100 ml of benzene was added and the solvents were distilled off. The mixture was cooled and 500 ml of water was then added. The formed crystals were fil-
trert av, vasket med vann og tørket i en ovn ved 50°C. stripped, washed with water and dried in an oven at 50°C.
Det ble oppnådd 40 g N-(1-(3'-hydroksypropyl) -2-pyrrolidinylmetyl)-2-metoksy-5-sulfamoylbenzamid med et utbytte på 72%. 40 g of N-(1-(3'-hydroxypropyl)-2-pyrrolidinylmethyl)-2-methoxy-5-sulfamoylbenzamide were obtained with a yield of 72%.
Benzamidet ble omdannet til hydrokloridet ved opp-løsning i absolutt alkohol og behandling med 50 ml 25%-ig etanol-isk .saltsyre. Det faste stoff som ble oppnådd ble.omkrystallisert fra metylalkohol. The benzamide was converted to the hydrochloride by dissolution in absolute alcohol and treatment with 50 ml of 25% ethanolic hydrochloric acid. The solid obtained was recrystallized from methyl alcohol.
Det ble oppnådd 38 g N-(1-(3'-hydroksypropyl)-2-pyrrolidinylmetyl)-2-metoksy-5^sulfamoylbenzamidhydroklorid i et 38 g of N-(1-(3'-hydroxypropyl)-2-pyrrolidinylmethyl)-2-methoxy-5-sulfamoylbenzamide hydrochloride were obtained in a
utbytte på .62,2% og med et smeltepunkt på 226-229°C. Eksempel 10: l--.( 2 ' -metoksy-4 ' -amino-benzamidopropyl) -4-h'ydroksy-etylpiperazindifosfat. yield of .62.2% and with a melting point of 226-229°C. Example 10: 1-(2'-methoxy-4'-amino-benzamidopropyl)-4-hydroxyethylpiperazine diphosphate.
2,8 g 2-metoksy-4-åminobenzosyre, 3,^ g l-(2 '-hydroksy-etyl )-4-(3'-aminopropyl)piperazin og 60 ml pyridin ble tilsatt til en 250 ml kolbe og 2,3 g silisiumtetraklorid ble tilsatt. dråp.evis. Blandingen ble oppvarmet i 3 timer ved tilbakeløpstemperatur. 2.8 g of 2-methoxy-4-aminobenzoic acid, 3.5 g of 1-(2'-hydroxyethyl)-4-(3'-aminopropyl)piperazine and 60 ml of pyridine were added to a 250 ml flask and 2, 3 g of silicon tetrachloride was added. death.news. The mixture was heated for 3 hours at reflux temperature.
Pyridinet ble destillert av i vakuum. Det ble tilsatt 30 ml vann fulgt av saltsyre inntil pH-verdien var 1. Blandingen ble oppvarmet til kokepunktet, filtrert etter undersøkelse,at pH-verdien fremdeles var sur, hvoretter ammoniakk ble tilsatt mens blandingen ennu var varm. The pyridine was distilled off in vacuo. 30 ml of water was added followed by hydrochloric acid until the pH was 1. The mixture was heated to the boiling point, filtered after checking that the pH was still acidic, after which ammonia was added while the mixture was still hot.
Etter avkjøling ble væsken dekantert fra bunnfallet. Det ble oppnådd 3,9 g 1-(2'-metoksy-4'-åminobenza-midopropyl)-4-hydroksyetylpiperazin i . et utbytte- på 69,65. After cooling, the liquid was decanted from the precipitate. 3.9 g of 1-(2'-methoxy-4'-aminobenzamidopropyl)-4-hydroxyethylpiperazine were obtained in . a dividend of 69.65.
Renhetsundersøkelse ved kvantitativ bestemmelse i ikke-vandig medium viste 97,5%. Purity examination by quantitative determination in a non-aqueous medium showed 97.5%.
Den oppnådde base ble oppløst i alkohol og deretter omdannet til det tilsvarende fosfat med fosforsyre.. Det oppnådde fosfat var et dobbeltfosfat som krystalliserte med 3 mol vann. The base obtained was dissolved in alcohol and then converted to the corresponding phosphate with phosphoric acid. The phosphate obtained was a double phosphate which crystallized with 3 mol of water.
'Det' ble oppnådd 3,2 g 1-(2'-metoksy-4'-aminobenzamidopropyl)-4-hydroksyetylpiperazindifosfat med et smeltepunkt på l44-l45°C. 'There' was obtained 3.2 g of 1-(2'-methoxy-4'-aminobenzamidopropyl)-4-hydroxyethylpiperazine diphosphate with a melting point of 144-145°C.
Benzamidene som fremstilles ifølge oppfinnelsen The benzamides produced according to the invention
har verdifulle terapeutiske egenskaper, spesielt som antieme-tika. Deres lave toksisitet tillater bruk i humanterapi uten risiko for sidevirkninger. has valuable therapeutic properties, especially as an antiemetic. Their low toxicity allows use in human therapy without the risk of side effects.
Den akutte toksisitet for de fremstilte produktene ble bestemt på mus på parenteral måte (endovenøs eller intraperitonealt). LD^-verdiene, beregnet ifølge Behrens og The acute toxicity of the manufactured products was determined in mice parenterally (endovenously or intraperitoneally). The LD^ values, calculated according to Behrens et
Karber, er angitt i følgende tabell: Carbs, are listed in the following table:
Den antiemetiske virkning for produktene som fremstilles i for- motvirkning av apomorfin - ble undersøkt på hunder ifølge Chen og Ensor slik denne teknikk var utviklet av Ducrot The antiemetic effect of the products which are prepared in the form of apomorphine - was investigated in dogs according to Chen and Ensor as this technique was developed by Ducrot
og Decourt. and Decourt.
'Resultatene som ble oppnådd er sammenlignet med de som ble oppnådd av Courvoisier for fenotiaziner og med de som ble oppnådd av Schallek for trimetobenzamid, og er angitt i følg-ende tabell. Aktivitetsindeksen er beregnet på subkutan måte med klorpromazin som referansestoff. The results obtained are compared with those obtained by Courvoisier for phenothiazines and with those obtained by Schallek for trimethobenzamide, and are given in the following table. The activity index is calculated subcutaneously with chlorpromazine as reference substance.
Disse resultater angir at .'forbindelsene som fremstilles mérkbårt er mere 'aktive som antiemétika'enn feridtiå-ziner og trimetobenzamid. These results indicate that the compounds produced are significantly more active as antiemetics than ferridthiazines and trimethobenzamide.
Claims (11)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7518001A FR2313935A1 (en) | 1975-06-10 | 1975-06-10 | NEW BENZAMIDES SUBSTITUTES, THEIR DERIVATIVES AND THEIR PREPARATION PROCESS |
Publications (3)
Publication Number | Publication Date |
---|---|
NO761977L NO761977L (en) | 1976-12-13 |
NO146058B true NO146058B (en) | 1982-04-13 |
NO146058C NO146058C (en) | 1982-07-28 |
Family
ID=9156239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO761977A NO146058C (en) | 1975-06-10 | 1976-06-09 | ANALOGY PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BENZAMIDES |
Country Status (37)
Country | Link |
---|---|
JP (1) | JPS6055503B2 (en) |
AR (1) | AR210888A1 (en) |
AT (1) | AT358571B (en) |
AU (1) | AU506001B2 (en) |
BE (1) | BE842059A (en) |
BG (1) | BG27360A3 (en) |
CA (1) | CA1064930A (en) |
CH (1) | CH596175A5 (en) |
CS (1) | CS189007B2 (en) |
DD (1) | DD124380A5 (en) |
DE (1) | DE2623075A1 (en) |
DK (1) | DK255276A (en) |
EG (1) | EG12285A (en) |
ES (1) | ES448643A1 (en) |
FI (1) | FI761669A (en) |
FR (1) | FR2313935A1 (en) |
GB (1) | GB1500105A (en) |
HK (1) | HK46979A (en) |
HU (1) | HU172195B (en) |
IE (1) | IE43375B1 (en) |
IN (1) | IN142899B (en) |
LU (1) | LU75104A1 (en) |
MW (1) | MW1676A1 (en) |
MX (1) | MX3580E (en) |
NL (1) | NL186382C (en) |
NO (1) | NO146058C (en) |
NZ (1) | NZ181072A (en) |
OA (1) | OA05350A (en) |
PH (1) | PH13912A (en) |
PL (2) | PL103075B1 (en) |
PT (1) | PT65164B (en) |
RO (1) | RO70265A (en) |
SE (1) | SE415971B (en) |
SU (2) | SU607551A3 (en) |
YU (1) | YU39352B (en) |
ZA (1) | ZA763042B (en) |
ZM (1) | ZM6576A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ186175A (en) * | 1977-01-27 | 1980-03-05 | Shionogi & Co | Meta-sulphonamidobenzamide derivatives |
FR2415099A1 (en) * | 1978-01-20 | 1979-08-17 | Ile De France | NEW DERIVATIVES OF 4-AMINO-5-ALKYLSULFONYL ORTHO-ANISAMIDES, THEIR METHODS OF PREPARATION AND THEIR APPLICATION AS PSYCHOTROPES |
FR2438650A1 (en) * | 1978-10-11 | 1980-05-09 | Ile De France | N- (1-METHYL 2-PYRROLIDINYL METHYL) 2,3-DIMETHOXY 5-METHYLSULFAMOYL BENZAMIDE AND DERIVATIVES THEREOF, THEIR PREPARATION METHODS AND THEIR APPLICATION IN THE TREATMENT OF LOWER URINARY DISORDERS |
JPS597160A (en) * | 1982-06-28 | 1984-01-14 | ラボラトリーオス・デラグランヘ・エセ・ア | N-(1-propyl-2-pyrrolidinylmethyl)-2-methoxy-5- sulfamoylbenzamide, manufacture and antidepressive |
US4820715A (en) * | 1984-06-28 | 1989-04-11 | Bristol-Myers Company | Anti-emetic quinuclidinyl benzamides |
US4808624A (en) * | 1984-06-28 | 1989-02-28 | Bristol-Myers Company | Pharmacologically active substituted benzamides |
US5011992A (en) * | 1984-06-28 | 1991-04-30 | Bristol-Myers Squibb Company | Pharmacologically active substituted benzamides |
JP3026845B2 (en) * | 1991-02-20 | 2000-03-27 | 日清製粉株式会社 | Piperidine derivative |
US9375486B2 (en) | 2012-09-17 | 2016-06-28 | Nektar Therapeutics | Oligomer-containing benzamide-based compounds |
-
1975
- 1975-06-10 FR FR7518001A patent/FR2313935A1/en active Granted
-
1976
- 1976-05-21 ZA ZA763042A patent/ZA763042B/en unknown
- 1976-05-21 BE BE1007404A patent/BE842059A/en not_active IP Right Cessation
- 1976-05-22 RO RO7686179A patent/RO70265A/en unknown
- 1976-05-22 DE DE19762623075 patent/DE2623075A1/en not_active Withdrawn
- 1976-05-24 AR AR263374A patent/AR210888A1/en active
- 1976-05-27 IN IN926/CAL/1976A patent/IN142899B/en unknown
- 1976-05-27 AU AU14360/76A patent/AU506001B2/en not_active Expired
- 1976-05-28 YU YU1318/76A patent/YU39352B/en unknown
- 1976-06-01 IE IE1166/76A patent/IE43375B1/en unknown
- 1976-06-01 AT AT400176A patent/AT358571B/en not_active IP Right Cessation
- 1976-06-01 PT PT65164A patent/PT65164B/en unknown
- 1976-06-02 EG EG326/76A patent/EG12285A/en active
- 1976-06-03 ZM ZM65/76A patent/ZM6576A1/en unknown
- 1976-06-04 CS CS763724A patent/CS189007B2/en unknown
- 1976-06-04 NZ NZ181072A patent/NZ181072A/en unknown
- 1976-06-04 BG BG033362A patent/BG27360A3/en unknown
- 1976-06-07 PH PH18542A patent/PH13912A/en unknown
- 1976-06-07 SU SU762362660A patent/SU607551A3/en active
- 1976-06-08 LU LU75104A patent/LU75104A1/xx unknown
- 1976-06-08 ES ES448643A patent/ES448643A1/en not_active Expired
- 1976-06-08 DD DD193235A patent/DD124380A5/xx not_active IP Right Cessation
- 1976-06-08 GB GB23695/76A patent/GB1500105A/en not_active Expired
- 1976-06-08 JP JP51067553A patent/JPS6055503B2/en not_active Expired
- 1976-06-08 SE SE7606424A patent/SE415971B/en not_active IP Right Cessation
- 1976-06-09 HU HU76SO00001171A patent/HU172195B/en unknown
- 1976-06-09 NO NO761977A patent/NO146058C/en unknown
- 1976-06-09 CA CA254,480A patent/CA1064930A/en not_active Expired
- 1976-06-09 MX MX76291U patent/MX3580E/en unknown
- 1976-06-09 PL PL1976190247A patent/PL103075B1/en not_active IP Right Cessation
- 1976-06-09 DK DK255276A patent/DK255276A/en unknown
- 1976-06-09 OA OA55847A patent/OA05350A/en unknown
- 1976-06-09 SU SU762366253A patent/SU645557A3/en active
- 1976-06-10 PL PL1976190304A patent/PL102929B1/en unknown
- 1976-06-10 MW MW16/76A patent/MW1676A1/en unknown
- 1976-06-10 CH CH736076A patent/CH596175A5/xx not_active IP Right Cessation
- 1976-06-10 FI FI761669A patent/FI761669A/fi not_active Application Discontinuation
- 1976-06-10 NL NLAANVRAGE7606284,A patent/NL186382C/en not_active IP Right Cessation
-
1979
- 1979-07-12 HK HK469/79A patent/HK46979A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI59990C (en) | FOERFARANDE FOER FRAMSTAELLNING AV PAO CENTRALNERVSYSTEMET VERKANDE RACEMISKA ELLER OPTISKT ACTIVE ARYLPIPERAZINER SAMT DERAS SYRAADDITIONSSALTER | |
US3819639A (en) | 2-metatrifluoromethylanilino-pyridine-5-n-acetyl sulfonamide | |
NO155805B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVITY 2- (4- (DIPHENYLMETHYL) -1-PIPERAZINYL) -ACDIC ACIDS AND THEIR AMIDS AND NON-TOXIC SALTS. | |
US4029673A (en) | N-(1-benzyl pyrrolidinyl 2-alkyl) substituted benzamides and derivatives thereof | |
EP0427765A1 (en) | Alkoxy-4(1h)-pyridone derivatives, processes for preparing them and their use as drugs | |
SU543341A3 (en) | Method for preparing benzylamine derivatives or their salts | |
CN109232541B (en) | Prolyl hydroxylase and histone deacetylase dual inhibitor and preparation method and application thereof | |
CA1092111A (en) | Sulfonamido-benzoic acid derivatives and process for the preparation thereof | |
NO146058B (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BENZAMIDES. | |
SU548207A3 (en) | The method of obtaining derivatives of 2-arylamino-2-imidazoline or their salts | |
AU644295B2 (en) | 2-aminopyrimidine-4-carboxamide derivatives, their preparation and their use in therapeutics | |
US2765338A (en) | New aliphatic acid amide derivatives and processes for the production thereof | |
US4578465A (en) | Phenyliperazine derivatives | |
IE902845A1 (en) | New oxazolopyridine derivatives, process for preparing them¹and pharmaceutical compositions containing them | |
NO124430B (en) | ||
IE921319A1 (en) | 2-aminopyrimidine-4-carboxamide derivatives, their¹preparation and their application in therapy | |
NO750713L (en) | ||
US3970661A (en) | 2-Amino, 5-carbamoyl pyridine compounds | |
US5198441A (en) | Derivatives of 1,2-dihydro 2-oxo quinoxalines, their preparation and their use in therapy | |
US3225091A (en) | Anticholinergic substituted butyramides | |
US5179089A (en) | Isoquinoline compounds, compositions and use | |
US3969356A (en) | N-[3-(p-f-benzoyl)-propyl]-N'-[2.(nitro,nitro-el, or methoxyphenyl)-ethyl]-p | |
KR810000357B1 (en) | Process for preparing substituted benzamides | |
CA1322755C (en) | Acetamide compounds | |
SU523634A3 (en) | Method for preparing benzylamine derivatives or their salts |